← Back to Clinical Trials
Recruiting NCT05444283

Genomic Predictors of Recurrent Pregnancy Loss

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Recurrent Pregnancy Loss
Sponsor Yale University
Study Type OBSERVATIONAL
Phase N/A
Enrollment 500
Sex ALL
Min Age 18 Years
Max Age 50 Years
Start Date 2021-09-01
Completion 2026-12

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The overall goals of this proposal are to determine the genetic architecture of recurrent pregnancy loss (RPL) and to discover genomic predictors of RPL.

Eligibility Criteria

Cohort A - Fetal Intolerome Cohort Inclusion Criteria: * Women with loss of a current singleton pregnancy at \< 20 0/7 weeks gestation, documented by ultrasonography or histopathological examination * History of one or more prior pregnancy losses * Euploid current pregnancy confirmed by karyotype, microarray, or STORK (Short-read Transpore Rapid Karyotyping) sequencing Note: A limited number of aneuploid losses will be included as part of the pilot phase Exclusion Criteria: * History of parental karyotype abnormalities * History of antiphospholipid antibody syndrome * Evidence of uncontrolled diabetes * Evidence of uncontrolled thyroid disease * History of autoimmune disease related to pregnancy loss (e.g., systemic lupus erythematosus, rheumatoid arthritis) * History of uterine anomalies * History of cervical insufficiency Cohort B - Maternal Effect Gene Cohort Inclusion Criteria: \- Women with a history of three or more pregnancy losses of unknown cause, with or without a liveborn ch

Related Trials

}
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology